We’re buying more of this life sciences stock after an earnings-driven decline
[ad_1] The stock is under pressure in early trading due to uncertainty around the recovery in a key business. [ad_2] Source link
Breaking News: Markets
Read More
When is it OK to violate your cost basis to buy more shares of a company?
[ad_1] Here’s our Club Mailbag email investingclubmailbag@cnbc.com — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries. This week’s question: The cardinal rule of discipline…
UnitedHealth is back and lifting other health-care stocks with it, Jim Cramer says
[ad_1] Traders work at the post where UnitedHealth Group is traded on the floor of the New York Stock Exchange. Brendan McDermid | Reuters UnitedHealth Group‘s (UNH) quality quarterly results Friday are a good sign for the broader health-care landscape, CNBC’s Jim Cramer said. The managed-care giant earned an adjusted $6.56 per share on revenues…
Here are 3 stocks in our portfolio that Goldman Sachs think will rally on earnings
[ad_1] It’s encouraging to see three Club stocks on the bullish side of Goldman Sachs’ new list of 25 tactical trades for earnings season. Asset allocation can be strategic or tactical. Strategic asset allocation generally refers to longer-term investing — think of this as your buy-and-hold approach. Tactical allocation, on the other hand, is more…
Monthly Meeting Q&A with Jim Cramer on everything from tech to health care to industrials
[ad_1] During the October Monthly Meeting , we took questions directly from Investing Club members. Here are Jim Cramer’s and portfolio director Jeff Marks’ responses. Their answers have been edited for clarity. 1. Why do rising interest rates have such a negative effect on technology stocks? (Rod) Jim Cramer: When the Federal Reserve started raising…
Here’s a rapid-fire update on all 36 stocks in our portfolio, including our latest addition
[ad_1] Jim Cramer ran through the names during the Club’s October Monthly Meeting on Wednesday. [ad_2] Source link
Jim Cramer praises Walgreens new CEO pick, says buy the stock ‘perhaps aggressively’
[ad_1] CNBC’s Jim Cramer on Wednesday praised the incoming CEO of Walgreens Boots Alliance, saying industry veteran Tim Wentworth is the right choice to lead the struggling pharmacy chain in its transition to offering more health-care services. “This guy is the real deal. I just salute him and think he can take you to a…
15 stocks with a history of dividend growth are expected to deliver once again this year
[ad_1] Broadcom (AVGO), Caterpillar (CAT) and Eli Lilly (LLY) are among the 15 Club stocks with a streak of annual dividend growth that Wall Street expects to continue in their current fiscal years. Long-term investors should look to own companies with a history of dividend growth instead of chasing stocks with high yields, Morgan Stanley…
Cramer says Vertex has a drug that may address the ‘largest market opportunity in the world’
[ad_1] CNBC’s Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing a drug to treat acute pain that is not an opioid. “The biggest pharmacy issue [is] how do we get pain removed, or at least nullified, without opiates? They have a plan — Vertex,” Cramer…
Here are all the portfolio moves the Club made in this week’s oversold market
[ad_1] With the stock market deeply oversold this week, we put cash to work by picking stocks across a range of sectors including energy, technology and materials. We also added a former Club chipmaker to our Bullpen and upgraded a premium beer name to a buy rating. Finally, Friday’s market reversal helped us make good…